AU2024259658A1 — Dosage regimen for a controlled-release PTH compound
Assigned to Ascendis Pharma Bone Diseases AS · Expires 2025-01-02 · 1y expired
What this patent protects
The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTH compound, which is a PTH moiety linked to a reversible prodrug linker, or a pharmaceutically acceptable salt, hydrate or solvate thereof. The controlled-release PTH comp…
USPTO Abstract
The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTH compound, which is a PTH moiety linked to a reversible prodrug linker, or a pharmaceutically acceptable salt, hydrate or solvate thereof. The controlled-release PTH compound is used in the treatment of hypoparathyroidism, wherein said pharmaceutical composition is administered by subcutaneous injection no more frequently than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 40% of the molar equivalent dose of PTH 1-84 of SEQ ID NO:1 administered subcutaneously every 24 hours required to maintain serum calcium within normal levels over said 24 hour period in humans.
Drugs covered by this patent
- Yorvipath (PALOPEGTERIPARATIDE) · Ascendis Pharma Bone
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.